PriceTargets.com logo

PhaseBio Pharmaceuticals - PHAS Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 04/24/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for PHAS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New PhaseBio Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHAS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHAS

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for PhaseBio Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for PHAS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in PhaseBio Pharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/24/2022CowenDowngradeOutperform ➝ Market PerformLow
10/24/2022CowenDowngradeMarket PerformLow
9/28/2022Stifel NicolausDowngradeBuy ➝ Hold$15.00 ➝ $1.00Low
9/28/2022Needham & Company LLCDowngradeBuy ➝ HoldLow
9/28/2022William BlairDowngradeOutperform ➝ Market PerformLow
8/15/2022Needham & Company LLCLower TargetBuy$10.00 ➝ $8.00Low
3/28/2022Needham & Company LLCLower TargetBuy$15.00 ➝ $10.00Low
10/13/2021Stifel NicolausInitiated CoverageBuy$15.00Medium
8/16/2021HC WainwrightReiterated RatingBuyHigh
6/17/2021Needham & Company LLCLower TargetBuy$16.00 ➝ $15.00Low
3/18/2021Stifel NicolausReiterated RatingBuy$8.00High
3/16/2021Needham & Company LLCBoost TargetBuy$18.00 ➝ $19.00High
8/25/2020CitigroupLower Target$12.00 ➝ $10.00High
8/11/2020Stifel NicolausReiterated RatingBuy$11.00Medium
5/29/2020CitigroupBoost Target$11.00 ➝ $12.00Medium
5/28/2020Needham & Company LLCInitiated CoverageBuy$18.00High
5/5/2020Stifel NicolausReiterated RatingBuy$4.00Medium
4/6/2020CitigroupLower TargetBuy$25.00 ➝ $11.00Low
12/20/2019HC WainwrightReiterated RatingBuy$18.00High
10/3/2019HC WainwrightInitiated CoverageBuy$18.00Low
9/24/2019CowenReiterated RatingBuyLow
9/11/2019William BlairReiterated RatingOutperformHigh
9/9/2019Stifel NicolausLower TargetBuy$20.00 ➝ $17.00Medium
5/24/2019CitigroupSet TargetBuy$27.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
PhaseBio Pharmaceuticals logo
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

848,888 shs

Market Capitalization

$3.50 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.57

Frequently Asked Questions

What sell-side analysts currently cover shares of PhaseBio Pharmaceuticals?

The following sell-side analysts have issued stock ratings on PhaseBio Pharmaceuticals in the last twelve months:
View the latest analyst ratings for PHAS.

What is the current price target for PhaseBio Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for PhaseBio Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for PhaseBio Pharmaceuticals in the next year.
View the latest price targets for PHAS.

What is the current consensus analyst rating for PhaseBio Pharmaceuticals?

PhaseBio Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PHAS.

What other companies compete with PhaseBio Pharmaceuticals?

Other companies that are similar to PhaseBio Pharmaceuticals include GeoVax Labs, Revelation Biosciences, Virpax Pharmaceuticals, Mustang Bio and Evoke Pharma. Learn More about companies similar to PhaseBio Pharmaceuticals.

How do I contact PhaseBio Pharmaceuticals' investor relations team?

PhaseBio Pharmaceuticals' physical mailing address is 1 Great Valley Parkway Suite 30, Malvern PA, 19355. The company's listed phone number is (610) 981-6500 and its investor relations email address is [email protected]. The official website for PhaseBio Pharmaceuticals is www.phasebio.com. Learn More about contacing PhaseBio Pharmaceuticals investor relations.